1Riddle mc . Glycenic mamagement of type 2 diabetes: an emerging strategy with oral agents , insulin and combinations [J]. Endocrinol Metab Clin North Am,2005,34:77-98
2K Bander Y Yamada, Glimepiride(Amaryl): a review of its pharmacologrcac and clinicaL profile[J]. Nippon Yakurigaku 2asshi,2001,118:59-67.
2[1]Muller G, Hartz D, Punter J, et al. Differential interaction of glimepiride and glibenclamide with the β -cell sulfonylurea receptor Ⅰ. Binding charatteristics[J]. Biochim Biophys Acta,1994; 1191:267-277.
3[2]Kramer W, Muller G, Girbig F, et al. Differential interaction of glimepiride and glibenclamide with the β-cell sulfonylurea receptor Ⅱ. Photoaffinity labeling of a 65 kDa protein by [3H] glimepiride[J]. Biochim Biophys Acta, 994;1191:278-290.
4[3]Sonnenberg GE, Garg DC, Weidler DJ, et al. Short-terrn comparison of once-versus twice-daily administration of glimepiride in patient with non-insulin-dependent diabetes mellitus[J]. Am Pharmacother,1997;31:671-676.
5[4]Muller G, Geisen K. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at adipocytes[J]. Horm Metab Res, 1996;28:468-487.
6Campbell RK.Glimepiride:role of a new sulfonylurea in the treatment of type 2 diabetes mellitus[J].Ann Pharmcother,1998,32(10):1044.
7Klepzig H,Kober G,Matter C,et al.Sulfonylureas and ischemic preconditioning:A double-blind,placebo-controlled evaluation of glimpiride and glibenclamide[J].Eur Heart J,1999,20(6):439.
